Rossari Biotech (ROSSARI) Fundamentals 2026 — P/E 18.2x, Revenue Analysis | SniperIQ
Rossari Biotech (ROSSARI) is a India-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ₹2,751 Crore, trading at ₹496.70 on the NSE. This SniperIQ fundamentals page covers Rossari Biotech's valuation (P/E 18.2x, P/B 2.1x), profitability (net margin 5.9%), revenue (₹2,396 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Rossari Biotech's market cap?
Rossari Biotech (ROSSARI) has a market capitalization of approximately ₹2,751 Crore, trading at ₹496.70 on the NSE. Market cap moves with the live share price.
What is Rossari Biotech's P/E ratio?
Rossari Biotech's trailing twelve-month P/E ratio is 18.2x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Rossari Biotech?
Rossari Biotech runs a net profit margin of 5.9%, a gross margin of 22.9%, and an operating margin of 8.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Rossari Biotech generate?
Rossari Biotech reported revenue of ₹2,396 Crore for fiscal year 2026, with net income of ₹149 Crore and earnings per share (EPS) of 26.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Rossari Biotech pay a dividend?
Rossari Biotech offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Rossari Biotech financially healthy?
Rossari Biotech carries a debt-to-equity ratio of 0.33x and a current ratio of 1.57x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Rossari Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Rossari Biotech (ROSSARI) the key facts are: market cap ₹2,751 Crore, P/E 18.2x, revenue ₹2,396 Crore, 52-week range 375-728.95. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Rossari Biotech's full fundamentals live
Get Rossari Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.